dRASTTM, direct & Rapid Antimicrobial Susceptibility Test

dRAST provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture in as low as 4 hours; reducing time to results by up to 2 days compared to conventional method. The rapid results allow for earlier optimization of antibiotics in critically-ill patients with bloodstream infections and sepsis.

  • Dedicated to positive blood culture samples
  • Provides phenotypic MIC in as low as 4 hours
  • Random access with up to 12 samples simultaneously (15 panel positions)
  • Expert system on board with choice of guidelines
  • Easy start with no McFarland required, no sample prep
  • 2 panels: 1 Gram Neg. + 1 Gram Pos.
  • Easy to use, fast to operate
  • No daily maintenance

QuantaMatrix's microbial diagnostics solutions are the first to be developed in Korea and have received the highest honors including the New Excellent Technology (NET) certification and new medical technology certification.

2 days faster than conventional AST

Conventional AST from blood can take at least three days or longer to produce results, as bacteria first has to be detected in blood and a pure isolate obtained before AST can proceed. dRAST, on the other hand, utilizes microfluidic technology and microscopic imaging technology that eliminates the need for pure isolate, to enable much faster results that can impact optimize antibiotic prescribing sooner.

Clinical Usefulness


Our dRAST test kit consists of Panel, Agarose, and Broth.

Gram negative, Gram positive


96-well plate with panel of dried-down antibiotics at various concentrations

QMAC-dRAST Agarose

Gel used for bacterial immobilization


Pipette tips and broth dispensed to enable bacterial growth

Gram-positive and Gram-negative panels using either CLSI or EUCAST recommended antimicrobials and breakpoints are available for dRAST.

  • CLSI panel: 17 Gram-positive , 19 Gram-negative antibiotics with multiple concentrations
  • EUCAST panel: 18 Gram-positive , 17 Gram-negative antibiotics with multiple concentrations
EUCAST panel Gram Positive
EUCAST panel Gram Negative
CLSI panel Gram Positive
CLSI panel Gram Negative

Clinical workflow

Technical workflow

drast workflow

User-friendly interface


  • Touchscreen user interface (UI)
  • Intuitive result reporting


  • Bi-directional LIS connectivity
  • Compatible with all major LIS


  • Random access and fully automated to improve workflow
  • Custom expert rules to accommodate individual lab guidelines


  • Integration with international and local guidelines (EUCAST, CLSI, and CA-SFM)
  • Real-time display of raw data and interpreted results
  • Display of MICs and SIR determination in a single screen
  • Activated comments and rules for each sample, allowing the clinicians and infectious disease specialists to get all the relevant information
Study 1
Study 2
Study 3

dRAST provides susceptibility test results with greater reliability at enhanced speed.

drast study
drast study

Analysis of susceptibility results generated by conventional testing methods took an average of 64.5 hours while results from dRAST direct from positive blood cultures only took 14.3 hours.

Susceptibility result from dRAST is not only rapid but also reliable. Compared to Broth Micro-Dilution (BMD), the overall agreement for dRAST was 94.2% (49/52) and 98.5% (66/67) for patients with gram-positive and gram-negative bacteremia, respectively.

Kim et al., Journal of Medical Microbiology 2018; 67: 325-331

Rapid AST is critical for timely prescribing of optimal, targeted antimicrobials.

A prospective study demonstrated the superior impact of dRAST on the selection of optimal antimicrobial therapy for resistant strains compared to Gram staining or MALDI-TOF MS identification.

The proportion of optimal targeted treatment was similar between the Gram-staining and the MALDI-TOF MS groups. However, there was significant improvement for the dRAST group compared to the MALDI-TOF MS group. The dRAST group demonstrated a 32% higher rate of optimal, targeted antimicrobial therapy compared to MALDI-TOF and the rate of ineffective therapy was 26% lower.

The study demonstrated that result of rapid AST using dRAST contributes significantly more than that of bacterial ID to the administration of optimal targeted antimicrobial treatment.

Kim et al., Journal of Antimicrobial Chemotherapy, Volume 74, Issue 8, August 2019, Pages 2255–2260

Rapid AST by dRAST enables successful implementation of antimicrobial stewardship even in the treatment of bacteremia in the immunosuppressed patients.

drast study

Rapid AST by dRAST enables successful implementation of antimicrobial stewardship even for immunosuppressed patients with bacteremia as well as those with underlying hematological disorders.

Deploying dRAST into the diagnostic process allows more timely management of optimal, targeted treatment. In a recent study, time to initiation of optimal, targeted antimicrobials decreased by 14 hours in the dRAST group (39.0 hrs) compared to the conventional AST group (53.2 hrs).

In addition, the proportion of patients receiving optimal, targeted treatment at 48 hours from the first blood draw higher was higher in the dRAST group (66.1%) compared to the conventional AST group (48.3%). Also, the proportion of patients receiving broad-spectrum treatment at 48 hours was lower in the dRAST group (21.4%) compared to the conventional AST group (31.7%).

Kim et al., Clin Microbiol Infect. Volume 27, Issue 1, 2021,Pages 69-75